Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Equol is a metabolite derived from the isoflavone daidzein, found in soy, and is notable for its selective estrogen receptor modulator (SERM) activity. The use of equol to support or treat premenstrual syndrome (PMS) is primarily based on its ability to bind to estrogen receptors and modulate estrogenic activity, which is thought to influence menstrual symptoms. Several small clinical trials and observational studies have investigated soy isoflavones (the precursors to equol) for their effects on PMS and menopausal symptoms, with mixed but generally positive results regarding symptom relief. However, not all individuals can naturally produce equol after consuming soy; thus, the use of proprietary or supplemental equol aims to standardize its availability and effects.

Direct scientific evidence specifically linking equol supplementation to significant improvement in PMS symptoms is limited. Most research focuses on menopausal symptoms rather than PMS. Some mechanistic studies suggest that equol’s affinity for estrogen receptor beta and its mild estrogenic/anti-estrogenic actions could help balance hormonal fluctuations implicated in PMS. While a few small studies suggest potential benefits, larger and well-designed randomized controlled trials are needed to confirm efficacy and safety.

In summary, while there is a plausible scientific rationale and some preliminary evidence for equol’s use in PMS, the current level of clinical evidence is modest. Therefore, the evidence is rated as 2 out of 5, reflecting early-stage scientific validation that requires further substantiation.

More about equol (proprietary)
More about PMS (general)

Other ingredients used for PMS (general)

Other health conditions supported by equol (proprietary)

Products containing equol (proprietary)